Baillie Gifford & CO Moderna, Inc. Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Moderna, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 42,458,083 shares of MRNA stock, worth $1.57 Billion. This represents 2.17% of its overall portfolio holdings.
Number of Shares
42,458,083
Previous 43,449,041
2.28%
Holding current value
$1.57 Billion
Previous $5.16 Billion
45.01%
% of portfolio
2.17%
Previous 4.1%
Shares
24 transactions
Others Institutions Holding MRNA
# of Institutions
952Shares Held
241MCall Options Held
10.6MPut Options Held
18.7M-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.49 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$944 Million0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$622 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$267 Million28.47% of portfolio
-
Geode Capital Management, LLC Boston, MA7.07MShares$261 Million0.04% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $14.5B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...